COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 26, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well COVID-19 vaccines work for patients who are currently being treated for cancer, including those with solid tumors and blood cancers. The researchers want to understand how different factors, such as the type of cancer treatment or the stage of disease, might affect the vaccine's effectiveness and how well the body responds to it. This study is taking place at two hospitals, Saint Louis Hospital and Bichat Hospital, and aims to gather important information that could help improve vaccine strategies for cancer patients.
To participate in this study, patients must be receiving treatment for cancer at one of the participating hospitals. This includes those undergoing chemotherapy, immunotherapy, targeted therapies, or radiation therapy. Patients who have any reasons that prevent them from getting vaccinated against COVID-19 will not be eligible. If you join the study, you can expect to receive the vaccine and have your response to it monitored, which will contribute valuable information to help other patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with malignant disease undergoing treatment at Saint Louis Hospital or Bichat Hospital (for chest cancer)
- • with chemotherapy
- • with chemotherapy + Immunotherapy
- • with immunotherapy
- • with targeted therapies
- • with radiotherapy
- • in the event of radiation pneumonitis after radiotherapy for lung cancers
- • after pneumonectomy for lung cancer
- • Patient informed and having expressed their non-opposition to participating in this research
- Exclusion Criteria:
- • Patient with a contraindication to Sars-Cov2 vaccination
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Paris, , France
Patients applied
Trial Officials
Luis TEIXEIRA, MD, PhD
Principal Investigator
Breast Disease Unit, Saint-Louis Hospital, APHP, Université de Paris, INSERM U976
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials